Document:

exv10w2

Exhibit 10.2

AMENDMENT NO. 1 TO

DISTRIBUTION AGREEMENT

     THIS AMENDMENT NO. 1 TO DISTRIBUTION AGREEMENT (this “Amendment No. 1”), effective as of
January 1, 2006 (the “Amendment Effective Date”), is entered into between FISHER SCIENTIFIC
COMPANY L.L.C., a Delaware limited liability company represented by its FISHER HEALTHCARE division,
(“FHC”), having a place of business at 9999 Veterans Memorial Drive, Houston, Texas 77038, and
BIOSITE INCORPORATED, a Delaware corporation (“Biosite”), having a place of business at 9975
Summers Ridge Road, San Diego, California 92121. Capitalized terms not defined herein shall have
the meanings set given to them in the Agreement.

RECITALS

     A. The
parties have entered into a Distribution Agreement effective as of
January 1, 2006 (the “Agreement”).

     B. The
parties now desire to amend the Agreement in certain respects on the
terms and conditions set forth below.

     NOW THEREFORE, in consideration of the foregoing premises and the mutual covenants set
forth below, the parties amend the Agreement and otherwise agree as follows:

     1. Amendments.

          1.1 Notwithstanding anything to the contrary in the Agreement, including
without limitation Sections 2(c) and 2(d), the “Territory” shall exclude Puerto Rico and the
US Virgin Islands.

     Accordingly, the first sentence of Section 2(c) is hereby amended and restated to
read as follows:

     “The “Territory” consists of two segments in the United States and its territories
(excluding Puerto Rico and the US Virgin Islands): (1) the “Hospital Medical Segment”, and
(2) the “Physician Medical Segment.”

     In addition, in the fourth sentence of Section 2(d), each reference to the phrase
“United States and its territories (including without limitation, Puerto Rico” shall be
hereafter replaced with the phrase “United States and its territories (excluding Puerto Rico
and the US Virgin Islands)”.

          1.2 Notwithstanding anything to the contrary in the Agreement, except with
respect to sales to customers in the Territory who have purchased any of the Products listed
on the attached Exhibit A (the “SOB Products”)
on or prior to March 31, 2006 ( “Pre-existing SOB
Product Customers”), the SOB Products shall be considered Increased Margin Products in the
Territory, and the “first sale of such Product by Biosite to FHC” under the Agreement shall be
deemed to have occurred on the Effective Date. For the avoidance of doubt any sales of SOB

1

 

Products
to Pre-existing SOB Product Customers, at any time, shall be deemed sales of Cardiac
Products as originally contemplated by the Agreement and the GSMR for sales of such Cardiac
Products shall be 11%. By not later than April 30, 2006, Biosite and Fisher shall mutually agree
to a list of those Pre-existing SOB Product Customers based on their respective business records.

     2. Miscellaneous.

          2.1
Continuing Effect. This Amendment No. 1 shall be effective for all
purposes as of the Amendment Effective Date. Except as otherwise expressly modified by this
Amendment No. 1, the Agreement shall remain in full force and effect in accordance with its
terms.

          2.2
Governing, Laws. This Amendment No. 1 shall be governed by,
interpreted and construed in accordance with the laws of the State of California, without regard to
conflicts of law principles.

          2.3
Counterparts. This Amendment No. 1 may be executed in counterparts,
each of which shall be deemed to be an original and together shall be deemed to be one and the
same document.

     IN WITNESS WHEREOF, the parties have caused this Amendment No. 1
to be executed by their
respective duly authorized officers as of the Amendment Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	BIOSITE INCORPORATED	 	 	 	FISHER SCIENTIFIC COMPANY L.L.C.
	 
	 	 	 	 	 	 	 	 	 	 
	     By:
	 	/s/ Robert B. Anacone	 	 	 	     By:	 	/s/ Kirk Kimler	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	     Title:
	 	Sr VP, WW Marketing and Sales	 	 	 	     Title:	 	President & General Manager	 	 

2

 

EXHIBIT A

SOB PRODUCTS

	 	 	 	 	 	 	 
	Catalog	 	 	 	 	 	 
	Number	 	Product	 	Size	 	List Price
	97300
	 	Triage ProfilER SOB Panel	 	25 tests	 	$1,175.00
	97301
	 	Triage ProfilER SOB Control Set (2x1)	 	 	 	$   100.00
	97303
	 	Triage ProfilER SOB Control Set (5x1)	 	 	 	$   100.00
	97305
	 	Triage ProfilER SOB Calibration Verification Samples	 	 	 	$     80.00

3exv10w3

Exhibit 10.3

Amendment No. 2 to Distribution Agreement

This
Amendment No. 2 to Distribution Agreement is entered Into effective as of June 30, 2008
(“Amendment Date”) between Inverness Medical Innovations
North America, Inc. (“Inverness”), a
Delaware corporation having a place of business at 30 South Keller
Road, Orlando, Florida 32810 (as successor by assignment from Biosite
Incorporated effective April 1, 2008), and Fisher Healthcare,
a division of Fisher Scientific Company L.L.C (“FHC”), having a place of business at 9999 Veterans
Memorial Drive, Houston, Texas 77038 and amends the Distribution
Agreement between the parties dated
January 1, 2006 (as amended, the “2006 Distribution Agreement”)

     The
parties mutually agree to amend the 2006 Distribution Agreement through this Amendment
No.2 on the terms and conditions below as follows:

     1. Defined
Terms. Any defined terms in this Amendment shall have the same meaning
designated in the 2006 Distribution Agreement unless otherwise expressly provided herein or in
Exhibits A and B of this Amendment.

     2. Extension of Non-Renewal Notice Period. Both parties agree that effective June
30, 2008 Section 6(a)(i) is hereby replaced it in its entirety with the following.

     “(1) unless
Inverness, in Inverness’s sole discretion, gives notice of non-renewal to FHC on
or before 11:59 Eastern Daylight Time July 8, 2008, this Agreement automatically shall be extended
for a period of one (1) year following the expiration of the Initial Term (the “First Extended
Term”), and -

     3.
Assignment. FHC hereby consents to the assignment of the 2008 Distribution
Agreement from Biosite Incorporated to Inverness effective as of
April 1, 2008.

     4. Miscellaneous.
Except as otherwise expressly modified by this Amendment, the 2006
Distribution Agreement shall remain in full force and effect in
accordance with its existing terms.
This Amendment may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same
instrument. In witness of
their agreement to the foregoing terms, the authorized representatives of each party have executed
this Amendment effective as of the Amendment Date.

	 	 	 	 	 	 	 	 	 	 	 
	Inverness Medical
Innovations North America,	 	 	 	Fisher HealthCare, a division of Fisher Scientific
	Company, L.L.C	 	 	 	 	 	 	 	 
	Inc.
	 	 	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:
	 	/s/ John Bridgen	 	 	 	By:	 	/s/ David Young	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Name:
	 	John Bridgen	 	 	 	Name:	 	David Young	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Title:
	 	VP, Business Development	 	 	 	Title:	 	VP, Finance	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 
	Date:
	 	June 27, 2008	 	 	 	Date:	 	June 27, 2008	 	 

 

 

	 	 	 	 	 
	By:
	 	/s/ Daniel J. Delaney	 	 
	 

	 	 

	 	 
	Name:
	 	Daniel J. Delaney	 	 
	 

	 	 

	 	 
	Title:
	 	Vice President	 	 
	 

	 	 

	 	 
	Date:
	 	June 27, 2008	 	 
	 

	 	 

	 	 

2exv10w4

Exhibit 10.4

Amendment No 2B to Distribution Agreement

This
Amendment No. 2B to Distribution Agreement is entered into effective as of July 8, 2008
(“Amendment Date”) between Inverness Medical Innovations North America, Inc. (“Inverness”), a
Delaware corporation having a place of business at 30 South Keller Road, Orlando. Florida 32810
(as successor by assignment from Biosite Incorporated effective April 1, 2008), and Fisher
HealthCare, a Division of Fisher Scientific Company, L.L.C. (“FHC”), having a place of business at
9999 Veterans Memorial Drive, Houston, Texas 77038 and amends the Distribution Agreement between
the parties dated January 1, 2006 (as amended, the “2006 Distribution Agreement”).

     The parties mutually agree to amend the 2006 Distribution Agreement through this Amendment
No. 2 on the terms and conditions below as follows:

     1. Defined Terms. Any defined terms in this Amendment shall have the same meaning
designated in the 2006 Distribution Agreement unless otherwise expressly provided in this
Amendment.

     2. Extension of Non-Renewal Notice Period. Both parties agree that effective July 8,
2008 Section 6(a)(i) is hereby replaced it in its entirety with the following:

     “(i)
unless Inverness, in Inverness’s sole discretion, gives notice of non-renewal to FHC on
or before 11:59 PM Eastern Daylight Time July 11, 2008, this 2006 Distribution Agreement
automatically shall be extended for a period of one (1) year following the expiration of the
Initial Term (the “First Extended Term”), and”

     3. Miscellaneous. Except as otherwise expressly modified by this Amendment, the 2006
Distribution Agreement shall remain in full force and effect in accordance with its existing terms. This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. In witness of their agreement to
the foregoing terms, the authorized representatives of each party have executed this Amendment
effective as of the Amendment Date.

	 	 	 	 	 	 	 	 	 
	Inverness Medical Innovations North America, Inc.	 	 	 	Fisher HealthCare
	 
	 	 	 	 	 	 	 	 
	By:

	 	/s/ Ron Zwanziger	 	 	 	By:	 	/s/ Joseph Bernando
	 

	 	 
	 	 	 	 	 	 
	Name:
	 	Ron Zwanziger	 	 	 	Name:	 	Joseph Bernando
	 

	 	 
	 	 	 	 	 	 
	Title:
	 	Chief Executive Officer	 	 	 	Title:	 	President
	Date:
	 	7/8/08	 	 	 	Date:	 	8 July 2008
	 
	 	 	 	 	 	 	 	 
	By:
	 	/s/ Ellen Chiniara	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	Name:
	 	Ellen Chiniara	 	 	 	 	 	 
	Title:
	 	Secretary	 	 	 	 	 	 
	Date:
	 	7/8/08

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00154-of-00352.parquet"}]]